Patenting Human Embryonic Stem Cells in the EU
This article was originally published in SRA
Executive Summary
As is common with many new technologies, there are challenges involved in attempting to patent new developments in the field of biotechnology and, in particular, in stem cell technology. Not least, there are ethical and moral questions surrounding the artificial creation of life or cloning, and concerning human dignity and the right to life. There is also debate over balancing the destruction of embryos against the need to develop potential therapeutic agents. Such questions have, unsurprisingly, fed through into the realms of stem cell patenting, since patenting goes directly to the heart of commercialising technology.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.